Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study
Molecular Class: Synthetic peptide research material Net Content: 10 mg Purity: Research-grade, high-purity peptide Material State: Lyophilized powder Intended Use: Laboratory research only Research Applications In published scientific and preclinical literature, Cagrilintide 10mg is described as a synthetic peptide research material examined within controlled experimental systems under non-clinical laboratory conditions
The objective of this study was to compare the efficacy and safety of tirzepatide with titrated insulin degludec in individuals with type 2 diabetes who had inadequate glycemic control despite treatment with metformin alone or in combination with SGLT2 inhibitors.In this phase 3 study, participants aged 18 years or older, with a baseline glycated hemoglobin (HbA1c) of 7.0-10.5%, body mass index of at least 25 kg/m2, stable weight, and no prior insulin treatment, were enrolled across multiple centers in 13 countries
Medication-specific injection site guidance While all GLP-1 medications use the same three injection sites, each medication has subtle differences worth considering when choosing your primary site
Lu dn ln da s gim hn vic hnh thnh cc np nhn cng nh du hiu lo ha n sm
How should GHK-Cu peptide injections be stored
